

MSACL 2016 EU

Davide Vecchietti¹, Daisuke Kawakami², Maura Brambilla³ ¹Shimadzu Italia, Milano, Italy, ²Shimadzu Corporation, Kyoto, Japan, ³Mass spectrometry Toxicology laboratory, Hospital Desio, Italy

PO-CON1693E

Introduction

Therapeutic drug monitoring of four major immunosuppressant drugs, Cyclosporine A, Tacrolimus, Sirolimus and Everolimus, is well established. Overdosing with these critical dose drugs can cause serious toxicity and long term morbidity, while organ rejection can occur if a patient is under dosed. Nowadays clinical laboratory has two main choices in technologies: immunoassay or chromatography based methods. LC–MS/MS's superior specificity makes it the presumptive gold standard in immunosuppressant quantitation. It relieves the method from common interferences that plague immunoassays such as metabolites that have structural resemblance and interfering antibodies. However, current LC–MS/MS platforms demand personnel expertise and tedious sample preparation and sample throughput is generally much lower compared to immunoassays. We report a fully automated procedure for the quantitation of four major immunosuppressant in whole blood samples, increasing data quality/precision, throughput and safety (The work described herein is for research use only).

Methods

The quantitative analysis of Immunosuppressant was performed using reagents provided in Chromsystems "MassTox[®]" ONEMinute Kit (ref, 93900). The Immunosuppressant and Internal standard were monitored using UHPLC-MS/MS system (Nexera X2 and LCMS-8050, Shimadzu, Kyoto, Figure 1)). Sample preparation was performed using Precipitation reagent, Extraction buffer and Internal standard set. Analytical performance of the method was monitored using whole blood calibrators and whole blood QC. Automatic sample preparation was performed using CLAM-2000 module (Shimadzu, Kyoto) Figure 1.



Figure 1: CLAM-2000 online with Nexera X2 system and LCMS-8050 triple quadrupole mass spectrometer.

Result and discussion

LC-MS/MS analysis

The Immunosuppressant standards and the Internal were firstly analysed by flow injection to optimize mass spectrometer parameters. All compounds were detected as positive ion choosing the MRM transitions listed in Table 2. Then Immunosuppressant standard mix was used to set-up chromatographic separation (Table 1).

[LC] NexeraX2 System	
Column Temp.	: 65 °C
Time Program	: 0.3 min (trap load); 1.5 min (elution); 2.3 min (stop)
Injection Volume	: 5 μL
[MS] LCMS-8050	
Ionization	: ESI Positive
Nebulizer Gas	: 3 L/min
Interface temperature	: 300 °C
Desolvation Line	: 250 °C
Heat Block temperature	: 400 °C
Drying Gas	: 10 L/min
Scan Type	: MRM

Table 1: Analytical Condition

Compound	MRM transition				
Cyclosporin A	1219.90 > 1202.80				
Tacrolimus	821.60 > 768.30				
Sirolimus	931.70 > 864.50				
Everolimus	975.70 > 908.50				
Cyclosporin A-d ₁₂	1231.90 > 1214.80				
Everolimus-d ₄	979.60 > 912.40				
Sirolimus-d₃	934.60 > 864.40				

824.60 > 771.40

Table 2: MRM Transitions

Fully Automated sample preparation

The CLAM-2000 was programmed to perform sample extraction and protein precipitation followed by filtration and sample collection. The filtrated sample was then automatically transported using an arm from the CLAM-2000 to the HPLC for LC-MS/MS analysis and no human intervention was required (Fig 2).

Tacolimus-13Cd₂




Figure 2: CLAM2000 fully automated sample preparation and analysis. Due to the overlapped sample preparation the throughput of the instrument was 1 result each 3.7 minutes for Immunosuppressant quantification.

Linearity, Accuracy and Precision

Linearity and Accuracy were evaluated using reference whole blood calibrators (7 levels) spanning from a wide range of concentrations (Cyclosporin 16.5 – 1100 µg/mL, Everolimus 0.86 – 32.7 µg/mL, Sirolimus 0.9 – 32.7 µg/mL, Tacrolimus 0.96 – 34.8 µg/mL). For all analytes

Linearity was >0.99 (see Table 3) with S/N >25 for LLOQ levels (Figure 3). Precision of the assay was evaluated using Chromsystems reference materials (whole blood controls levels) spanning from low concentration to highest concentration for each analyte (Table 4).

Compound	Accuracy	r ²
Cyclosporin A	90.4%-103.6%	0.998
Tacrolimus	99.7%-101-3%	0.997
Sirolimus	95.1%-105.5%	0.998
Everolimus	96.9%-107%	0.998

Table 3: Linearity & Accuracy.




Figure 3: Linearity and LLOQ.

	Ref. Level (ug/L)	CV% (intra-assay)*	BIAS% (intra-assay)*	CV% (inter-assay)**	BIAS% (inter-assay)**
Cyclosporin	Low (16.5)	6.0%	1.70%	7.9%	1.68%
	Mid (49.7)	2.2%	1.33%	4.3%	1.22%
	High (1100)	1.83%	2.56%	5.8%	3.08%
Tacrolimus	Low (2.86)	3.29%	2.95%	5.6%	3.58%
	Mid (7.73)	2.69%	8.00%	4.7%	12.33%
	High (34.8)	2.76%	1.85%	4.4%	6.57%
Sirolimus Mid (9	Low (2.76)	1.02%	2.68%	3.7%	5.59%
	Mid (9.89)	2.44%	12.18%	4.1%	14.77%
	High (32.7)	2.59%	6.01%	4.9%	12.99%
Everolimus	Low (2.6)	2.04%	4.54%	8.9%	6.44%
	Mid (4.79)	5.98%	7.16%	8.2%	11.77%
	High (32.7)	2.55%	4.75%	3.3%	7.64%

Table 4: Repetability, Reproducibility , Accuracy, evaluated using Chromsystems reference controls.* n=7 . ** n=3 non consecutive days with instrument shutdown.

Methods correlation

Real samples (EDTA whole blood from patients treated with Tacrolimus) were analyzed using both manual sample preparation and fully automated sample preparation (CLAM-2000). The Tacrolimus concentration obtained by the two sample preparation methods shown a good agreement (Figure 4 B). Moreover the Tacrolimus concentration in 59 whole blood real samples was evaluated with Immunoassay and CLAM-2000 LC-MS/MS approaches. As shown by Passing and Bablok plots (Figure 4 A) there was a good agreement between the two different methods of quantification.




Figure 4: Methods comparison. A) n=59 real samples Tacrolimus. B) n=20 real samples Tacrolimus.



Conclusions

- Fully Automated sample preparation procedure resulted suitable for the quantitation of Immunosuppressant by elimination of all manual preparation steps.
- The automation of the method increases the analytical performance, reduces the risk for human operators and, due to the reduced reagent consumption, reduces also the cost of the analysis.

Disclaimer: The products and applications in this presentation are intended for Research Use Only (RUO). Not for use in diagnostic procedures. Not available in the USA, Canada and China.

First Edition: October, 2016



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures. Not available in the USA, Canada, and China. This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.